Zacks Investment Research
23 Oct 2026, 11:51 UTC · 3h ago
Impact · against what's priced in
KRRO is a buy on positive preclinical data for KRRO-111 and a concrete 2027 regulatory timeline. While widening losses are a headwind, the clinical progress outweighs the short-term burn for this early-stage biotech.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 2 new · 2 priced in
Korro Bio announced positive preclinical results for KRRO-111, which restored functional M-AAT protein and reduced harmful Z-AAT protein in animal studies.
Newannounced on publication date October 23, 2026
More positive than 99% of claims this week
Korro Bio plans to submit a regulatory filing for KRRO-111 in the first half of 2027.
New
Continue reading
5 related stories
Positive preclinical results for KRRO-111 showing protein restoration in animal studies and a target regulatory filing in H1 2027 provide a tangible catalyst for valuation.
Read from the article alone
No priced-in read yet
The article mentions DERM only as a peer in the same industry; there is no company-specific news affecting its fundamentals.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 87% of claims this week
The company is expected to report a quarterly loss of $1.14 per share, a 40.6% increase year-over-year.
Priced inanalysis of expected upcoming report
So whatWidening losses suggest an increasing cash burn rate that may necessitate future equity financing to reach the 2027 filing milestone.
More negative than 77% of claims this week
Expected revenues for the upcoming quarter are $1.5 million, representing a 37.6% increase from the prior year.
Priced inanalysis of expected upcoming report
So whatDespite growth, the $1.5M revenue scale remains negligible relative to the $1.14 per share loss.
More positive than 54% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
18h ago
−3.2%
Price is moving against the score
$11.66 vs $12.05 close before publication (Oct 22) · not market-adjusted
KRRO chart →−4.3%
$4.87 vs $5.09 close before publication (Oct 22) · not market-adjusted
DERM chart →
